Comparison

Goat anti Apo E

Manufacturer GENWAY
Category
Type Antibody
Specific against other
Applications WB, ELISA
Amount 1 mg
Host Goat
Item no. 18-511-245352
eClass 6.1 32160702
eClass 9.0 32160702
Available
Genway ID:
GWB-C184A0
Host Animal:
Goat
Immunogen:
Purified human Apo E from human plasma
Specificity:
Apolipoprotein E (Apo E)
Specificity:
Binds to Apo E. Recognizes isoforms E2 E3 and E4. No cross-reaction to Apo AI Apo AII Apo CI Apo CII and Apo CIII.
Type of Product:
Polyclonal Antibodies to Lipoproteins
Concentration:
1mg/ml (OD280nm E0. 1% = 1. 35)Preservatives: NaN3
Buffer:
75mM PBS 75mM Sodium chloride 0. 5mM EDTA pH 7. 2Applications Notes : Can be used for detection of Apo E in plasma and lipoproteins; for immunoassay immunoblot enzyme conjugation biotinylation. Dilution for immunoblot and ELISA: 1:10 000 to 1:80 000 . Each laboratory should determine an optimum working titer for use in its particular application. Other applications have not been tested but use in such assays should not necessarily be excluded.
Warning:
This product contains sodium azide which has been classified as Xn (Harmful) in European Directive 67/548/EEC in the concentration range of 0. 1â ??1. 0%. When disposing of this reagent through lead or copper plumbing flush with copious volumes of water to prevent azide build-up in drains. Goat anti Apo E. Goat Antibody to Human Apolipoprotein E (Apo E)
Function:
Mediates the binding internalization and catabolism of lipoprotein particles. It can serve as a ligand for the LDL (apo B/E) receptor and for the specific apo-E receptor (chylomicron remnant) of hepatic tissues.
Subcellular Location:
Secreted.
Tissue Specificity:
Occurs in all lipoprotein fractions in plasma. It constitutes 10-20% of very low density lipoproteins (VLDL) and 1-2% of high density lipoproteins (HDL). APOE is produced in most organs. Significant quantities are produced in liver brain spleen lung adrenal ovary kidney and muscle.
Ptm:
Synthesized with the sialic acid attached by O-glycosidic linkage and is subsequently desialylated in plasma.
Ptm:
Glycated in plasma VLDL of normal subjects and of hyperglycemic diabetic patients at a higher level (2-3 fold).
Polymorphism:
Three common APOE alleles have been identified: APOE*2 APOE*3 and APOE*4. The corresponding three major isoforms E2 E3 and E4 are recognized according to their relative position after isoelectric focusing. Different mutations causing the same migration pattern after isoelectric focusing define different isoform subtypes. The most common isoform is E3 and is present in 40-90% of the population. Common APOE variants influence lipoprotein metabolism in healthy individuals.
Disease:
Defects in APOE are a cause of hyperlipoproteinemia type III [MIM:107741]; also known as familial dysbetalipoproteinemia. Individuals with hyperlipoproteinemia type III are clinically characterized by xanthomas yellowish lipid deposits in the palmar crease or less specific on tendons and on elbows. The disorder rarely manifests before the third decade in men. In women it is usually expressed only after the menopause. The vast majority of the patients are homozygous for APOE*2 alleles. More severe cases of hyperlipoproteinemia type III have also been observed in individuals heterozygous for rare APOE variants. The influence of APOE on lipid levels is often suggested to have major implications for the risk of coronary artery disease (CAD). Individuals carrying the common APOE*4 variant are at higher risk of CAD.
Disease:
The APOE*4 allele is associated with late onset Alzheimer disease 2 (AD2) [MIM:104310]. The APOE*4 allele is genetically associated with the common late onset familial and sporadic forms of Alzheimer disease (AD). Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE*4 alleles in 42 families with late onset AD. Thus APOE*4 gene dose is a major risk factor for late onset AD and in these families homozygosity for APOE*4 was virtually sufficient to cause AD by age 80. The mechanism by which APOE*4 participates in pathogenesis is not known.
Disease:
Defects in APOE are a cause of sea-blue histiocyte disease [MIM:269600]; also called sea-blue histiocytosis. This disorder is characterized by splenomegaly mild thrombocytopenia and in the bone marrow numerous histiocytes containing cytoplasmic granules which stain bright blue with the usual hematologic stains. The syndrome is the consequence of an inherited metabolic defect analogous to Gaucher disease and other sphingolipidoses.
Disease:
Defects in APOE are a cause of lipoprotein glomerulopathy (LPG) [MIM:611771]. LPG is an uncommon kidney disease characterized by proteinuria progressive kidney failure and distinctive lipoprotein thrombi in glomerular capillaries. It mainly affects people of Japanese and Chinese origin. The disorder has rarely been described in Caucasians.
Similarity:
Belongs to the apolipoprotein A1/A4/E family.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 1 mg
Available: In stock
available

Delivery expected until 5/30/2024 

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close